Pharmacotherapy of intermittent claudication

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 11, 2001, Pages 1725-1736

  Doggrell, S A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Basic fibroblast growth factor; Cilostazol; Glyceryl trinitrate; Intermittent claudication; L arginine; Naftidrofuryl; Pentoxifylline; Propionyl L carnitine; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; AS 103; BASIC FIBROBLAST GROWTH FACTOR; CARNITINE; CILOSTAZOL; DEFIBROTIDE; ENZYME ACTIVATOR; ENZYME INHIBITOR; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; INDOBUFEN; KETANSERIN; LIPOPROTEIN LIPASE; LOW MOLECULAR WEIGHT HEPARIN; MICROSPHERE; MILRINONE; NAFTIDROFURYL; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE; PROPIONYLCARNITINE; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; SEROTONIN ANTAGONIST; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTERY DISEASE; BLOOD DYSCRASIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EXERCISE; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INTERMITTENT CLAUDICATION; LEG PAIN; LIMB AMPUTATION; META ANALYSIS; MUSCLE CRAMP; MYALGIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYMPTOM; THROMBOCYTE AGGREGATION; WALKING;

ANIMALS; ANTICOAGULANTS; CARDIOTONIC AGENTS; CARNITINE; HUMANS; INTERMITTENT CLAUDICATION; NAFRONYL; NITRIC OXIDE; PENTOXIFYLLINE; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; VASODILATOR AGENTS;

EID: 0035169777     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.11.1725     Document Type: Review

References (60)

1. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-1985
2. Intermittent claudication. A risk profile for The Framingham Heart Study
3. Die chirurgische Behandlung der peripheren Durchblutungsstörungen
4. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis
5. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study
6. Cytokines, Phagocytes, and Pentoxifylline
7. Management of intermittent claudication with pentoxyifylline: Meta-analysis of randomised controlled trials
8. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells
9. Cilostazol, a selective Type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
10. Inhibition of adenosine uptake and augmentation of ischaemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication
11. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease
12. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
13. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomised, prospective, double-blind trial
14. A new pharmacological treatment for intermittent claudication: Results of a randomised, multicenter trial
15. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
16. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
17. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease
18. Effect of naftidrofuryl on platelet aggregation in plasma form aspirin treated patients: An in vitro study
19. Antithrombotic drugs in the primary medical management of intermittent claudication: A meta-analysis
20. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Finding of the Naftidrofuryl Clinical ischaemia Study (NCIS)
21. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication
22. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial
23. Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication
24. Multiple double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications
25. Long-term effects of ticlopidine on lower limb blood flow, ankle/arm index and symptoms in peripheral arteriosclerosis. A double-blind study
26. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopodine Multicentre Study (STIMS)
27. Hematologic dyscrasia associated with ticlopidine therapy: Evidence for causality
28. A randomised, double-blind, placebo-controlled, crossover study to assess the immediate effect of sublingual glyceryl trinitrate on the ankle brachial pressure index, claudication, and maximum walking distance of intermittent claudication
29. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
30. Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: A H215O positron emission tomography study
31. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease
32. Randomised trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication
33. Improvement of walking distance by defibrotide in patients with intermittent claudication -results of a randomised, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study
34. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: Results of a multicenter placebo-controlled double-blind trial
35. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication
36. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PDG1)
37. Randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication
38. A meta-analysis of randomised placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease
39. A dose-effect study of beraprost sodium in intermittent claudication
40. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: A double-blind, randomised, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group
41. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: A double-blind, cross-over study
42. Superiority of L-propionlycarnitine vs. L-carnitine in improving walking capacity in patients with peripheral vascular disease: An acute, intravenous, double-blind, cross-over study
43. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study
44. Effect of propionyl-L-carnitine on quality of life in intermittent claudication
45. European multicenter study on propionly-L-carnitine on intermittent claudication
46. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peripheral and cerebral vascular diseases
47. A meta-analysis of randomised, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication
48. Oral vasoactive medication in intermittent claudication: Utile or futile?
49. Effect of verapamil in intermittent claudication. A randomised, double-blind, placebo-controlled, cross-over study after individual dose-response assessment
50. Effects of policosanol in patients with Type II hypercholesterolemia and additional coronary risk factors
51. Effect of policosanol on platelet aggregation in Type II hypercholesterolemic patients
52. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
53. A long-term study of policosanol in the treatment of intermittent claudication
54. Effect of cloricromene on intermittent claudication. A randomised, double-blind, placebo-controlled trial in patients treated with aspirin: Effect on claudication distance and quality of life
55. Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication in male smokers
56. The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial
57. Ginkgo biloba leaf extract: Review of biological actions and clinical applications
58. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication - A placebo-controlled, double-blind multicenter trial
59. Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomised trials
60. Basic fibroblast growth factor in patients with intermittent claudication: Results of a Phase I trial